When was D&D Pharmatech founded?

D&D Pharmatech was founded in 2014 and raised its 1st funding round 4 years after it was founded.

Where is D&D Pharmatech located?

D&D Pharmatech is headquartered in Seongnam-si, South Korea.

How many employees does D&D Pharmatech have?

As of Feb 28, 2026, the latest employee count at D&D Pharmatech is 60.

Is D&D Pharmatech a funded company?

D&D Pharmatech is a funded company, having raised a total of $205M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 2018.

When was the latest funding round of D&D Pharmatech?

D&D Pharmatech's latest funding was a $***** Post IPO round on Jun 20, 2025, with participation from 0 investor.

Where does D&D Pharmatech rank among its competitors?

D&D Pharmatech ranks 10th amongst 504 active competitors, of which 182 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of D&D Pharmatech?

D&D Pharmatech's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Adocia. Among them, Alchemab secured the most recent funding round in July, 2026.

D&D Pharmatech - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of GLP-1-based therapeutics for metabolic disease treatment. It focuses on building on a robust foundation of proprietary peptide research and strategic collaborations. D&D Pharmatech is advancing a diverse pipeline of therapeutics for metabolic, fibrotic, and neurodegenerative diseases. The global biotech company’s umbrella structure comprises three U.S. subsidiaries, including Neuraly Inc, its clinical research arm responsible for conducting clinical trials for the company’s pipeline, including its dual agonist (GLP-1/glucagon) for metabolic dysfunction-associated steatohepatitis (MASH).

Website: ddpharmatech.com
Email ID: *****@ddpharmatech.com, *****@ddpharmatech.com, *****@ddpharmatech.com
Phone Number: +82 **********

Key Metrics

Founded Year

2014

Location

Seongnam-si, South Korea

Stage

Public

Total Funding

$205M in 5 rounds

Latest Funding Round

Post IPO, Jun 20, 2025, $*****

Investors

Praxis Capital & 11 more

Ranked

10^th among 504 active competitors

Employee Count

60 as on Feb 28, 2026

Investment & Acquisitions

Neuraly

Similar Companies

Denali Therapeutics & 618 more

Exit Details

Public

View D&D Pharmatech's full profile

D&D Pharmatech is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
D&D Pharmatech Co., Ltd. CIN: 120-88-21933 , South Korea, Active	Dec 27, 2014	-	-	-

D&D Pharmatech got listed on May 02, 2024.

Click here to take a look at D&D Pharmatech's IPO in detail

D&D Pharmatech has raised a total funding of $205M over 5 rounds. Its first funding round was on Mar 2018. D&D Pharmatech has 12 institutional investors.

Here is the list of recent funding rounds of D&D Pharmatech:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 20, 2025	1487097	Post IPO	6986740	7379613	9912799	1109374
Oct 19, 2021	5010184	Series C	1296845	4146380	6626666	DS & 2 more
Feb 18, 2020	3268896	Grant (prize money)	7188471	3428922	5752210	Alzheimer's Drug Discovery

Access funding benchmarks and valuations. Sign up today!

View details of D&D Pharmatech's funding rounds and investors

The founders of D&D Pharmatech is Seulki Lee.

Here are the details of D&D Pharmatech's key team members:

Seulki Lee: Founder of D&D Pharmatech.

View details of D&D Pharmatech's Founder profiles and Board Members

D&D Pharmatech's employee count trend

D&D Pharmatech has 60 employees as of Feb 26. Here is D&D Pharmatech's employee count trend over the years:

Uncover D&D Pharmatech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of D&D Pharmatech include Denali Therapeutics, Fulcrum Therapeutics and Adocia. Here is the list of Top 10 competitors of D&D Pharmatech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
4th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
5th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Blackstone, Redmile Group & 17 others	67/100
6th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Sanofi & 5 others	65/100
8th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	65/100
9th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	64/100
10th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Smile Gate Investment, Octave Ventures & 10 others	64/100